US-based Veradigm has announced an investment in Holmusk, a global behavioural health real-world evidence and data analytics company in Singapore, as part of Holmusk’s $45 million series B financing round. The round was led by Veradigm, with participation from current investors including Heritas Capital, Health Catalyst Capital, Novartis (dRx Capital), and Northwell Holdings, the venture investment arm of Northwell Health, as well as other previous investors.

Holmusk will leverage this investment to continue its rapid expansion of its flagship offering, the NeuroBlu Database, a leading source of real-world clinical data for the behavioral health industry.

Now that the financing has been completed, Veradigm and Holmusk intend to enter into a data partnership to bring cohorts of behavioural health and related de-identified patient data from Veradigm to the NeuroBlu Database, significantly adding to Holmusk’s real-world clinical data asset.

“This investment will enable our team to continue its work in curating and enhancing data as we plan to build the world’s largest platform for behavioural health data,” said Nawal Roy, Founder and CEO, Holmusk.